Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai…
In the Era of Generic Cardiovascular Agents, Can Emerging Therapies Achieve Substantial Clinical Differentiation to Gain Widespread Use? Chronic heart failure (CHF) describes the long-term…
In the Era of Generic Cardiovascular Agents, Can Emerging Therapies Achieve Substantial Clinical Differentiation to Gain Widespread Use? Chronic heart failure (CHF) describes the long-term…
What attributes will distinguish emerging therapies in the eyes of oncologists and payers? Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for…
What attributes will distinguish emerging therapies in the eyes of oncologists and payers? Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for…
Venous thromboembolism (VTE) is a potentially fatal cardiovascular condition characterized by the development of a thrombus in the vasculature. Treatment options for VTE have been largely limited…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
Myelodysplastic syndromes (MDS) consists of a group of disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis and deteriorating…
In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States,…
In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States,…
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing a…